Meeting
2017 Genitourinary Cancers Symposium
A phase II study of alternative sunitinib scheduling in patients with metastatic renal cell carcinoma.
Authors
Eric Jonasch
The University of Texas MD Anderson Cancer Center, Houston, TX
Eric Jonasch , Rebecca Slack , Daniel M. Geynisman , Matthew I. Milowsky , Kimryn Rathmell , Summer Stovall , Donna Juarez , Elizabeth R. Plimack , Nizar M. Tannir , Brian I. Rini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer
Track
Renal Cell Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT02060370
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 533)
DOI
10.1200/JCO.2017.35.6_suppl.533
Abstract #
533
Poster Bd #
G27
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase II study of alternate sunitinib schedule in patients with metastatic renal cell carinoma.
First Author: Eric Jonasch
Poster
2022 ASCO Genitourinary Cancers Symposium
Randomized phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Final analysis of SURF study.
First Author: Antoine Thiery-Vuillemin
Poster
2013 Genitourinary Cancers Symposium
Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma.
First Author: Yana George Najjar
Poster
2019 Genitourinary Cancers Symposium
Fecal microbiota transplantation for TKI-induced diarrhea in patients with metastatic renal cell carcinoma.
First Author: Ernesto Rossi